Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Identifieur interne : 000478 ( Main/Exploration ); précédent : 000477; suivant : 000479Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Auteurs : R B Postuma [Canada] ; J F Gagnon [Canada] ; J. Montplaisir [Canada]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2010-09.
Abstract
As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.
Url:
DOI: 10.1136/jnnp.2009.174748
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name></author><author><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J F" last="Gagnon">J F Gagnon</name></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB55C749FE4F99EFA48E8968C7286E7159E3AE22</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1136/jnnp.2009.174748</idno><idno type="url">https://api.istex.fr/document/BB55C749FE4F99EFA48E8968C7286E7159E3AE22/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000583</idno><idno type="wicri:Area/Main/Curation">000508</idno><idno type="wicri:Area/Main/Exploration">000478</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre d'etude du sommeil, Hopital du Sacre-Coeur, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J F" last="Gagnon">J F Gagnon</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre d'etude du sommeil, Hopital du Sacre-Coeur, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Département de psychiatrie, Université de Montréal</wicri:regionArea><wicri:noRegion>Université de Montréal</wicri:noRegion></affiliation></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name><affiliation wicri:level="3"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre d'etude du sommeil, Hopital du Sacre-Coeur, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Département de psychiatrie, Université de Montréal</wicri:regionArea><wicri:noRegion>Université de Montréal</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2010-09">2010-09</date><biblScope unit="volume">81</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1008">1008</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">BB55C749FE4F99EFA48E8968C7286E7159E3AE22</idno><idno type="DOI">10.1136/jnnp.2009.174748</idno><idno type="href">jnnp-81-1008.pdf</idno><idno type="ArticleID">jnnp174748</idno><idno type="PMID">20562452</idno><idno type="local">jnnp;81/9/1008</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name></region><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J F" last="Gagnon">J F Gagnon</name><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J F" last="Gagnon">J F Gagnon</name><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000478 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000478 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BB55C749FE4F99EFA48E8968C7286E7159E3AE22
|texte= Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
}}
| This area was generated with Dilib version V0.6.23. |  |